MCP-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo
© Jin et al.; licensee BioMed Central. 2015
Received: 31 August 2014
Accepted: 10 February 2015
Published: 27 February 2015
Minocycline, a broad-spectrum tetracycline antibiotic, has shown anti-inflammatory and neuroprotective effects in ischemic brain injury. The present study seeks to determine whether monocyte chemotactic protein-induced protein 1 (MCPIP1), a recently identified modulator of inflammatory reactions, is involved in the cerebral neuroprotection conferred by minocycline treatment in the animal model of focal cerebral ischemia and to elucidate the mechanisms of minocycline-induced ischemic brain tolerance.
Focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) for 2 h in male C57BL/6 mice and MCPIP1 knockout mice followed by 24- or 48-h reperfusion. Twelve hours before ischemia or 2 h after MCAO, mice were injected intraperitoneally with 90 mg/kg of minocycline hydrochloride. Thereafter, the animals were injected twice a day, at a dose of 90 mg/kg after ischemia until sacrificed. Transcription and expression of MCPIP1 gene was monitored by quantitative real-time PCR (qRT-PCR), Western blot, and immunohistochemistry. The neurobehavioral scores, infarction volumes, and proinflammatory cytokines in brain and NF-κB signaling were evaluated after ischemia/reperfusion.
MCPIP1 protein and mRNA levels significantly increased in mouse brain undergoing minocycline pretreatment. Minocycline treatment significantly attenuated the infarct volume, neurological deficits, and upregulation of proinflammatory cytokines in the brain of wild type mice after MCAO. MCPIP1-deficient mice failed to evoke minocycline-treatment-induced tolerance compared with that of the control MCPIP1-deficient group without minocycline treatment. Similarly, in vitro data showed that minocycline significantly induced the expression of MCPIP1 in primary neuron-glial cells, cortical neurons, and reduced oxygen glucose deprivation (OGD)-induced cell death. The absence of MCPIP1 blocked minocycline-induced protection on neuron-glial cells and cortical neurons treated with OGD.
Our in vitro and in vivo studies demonstrate that MCPIP1 is an important mediator of minocycline-induced protection from brain ischemia.
KeywordsIschemic stroke Minocycline Monocyte chemotactic protein-induced protein 1 (MCPIP1) Middle cerebral artery occlusion (MCAO) Proinflammatory cytokines
Significant advances have been made to lessen the immense public health problem of stroke. Endeavors in prevention have brought down stroke incidence and mortality, and the establishment of exceptional intensive care units has ameliorated the functional consequence of stroke victims [1,2]. However, limited approaches have been made in developing therapies to decrease the detrimental effects of cerebral ischemia. It has been demonstrated that the brain has a marvelous capacity for self-preservation, elucidated by the protective responses induced by ischemia and preconditioning . Understanding the mechanisms underlying these protective actions will help to minimize ischemic brain injury.
Minocycline, a tetracycline antibiotic, manifests anti-inflammatory, anti-apoptotic, and neuroprotective effects independent of its broad-spectrum antimicrobial activity [3-7]. Its superior penetration to the brain tissue, good clinical safety, and prolonged therapeutic window makes it an ideal candidate for application in the treatment of stroke . Although the observed neuroprotection of minocycline in ischemic stroke reflects some properties that mimic selected features of endogenous neuroprotection, it is still unclear whether minocycline acts solely by engaging endogenous neuroprotective mechanisms .
Monocyte chemotactic protein-induced protein 1 (MCPIP1) was discovered as an inducible protein expressed in human peripheral blood monocytes treated with monocyte chemotactic protein 1 (MCP-1) . Our previous reports demonstrated that MCPIP1 was a negative regulator of macrophage activation and that MCPIP1 inhibited the production of proinflammatory cytokines, such as TNFα, IL-1β, IL-6, and MCP-1, by inhibiting the activity of JNK and NF-κB proinflammatory signal pathways [10,11]. Our further studies indicated that MCPIP1 was also inducibly expressed in macrophages, endothelial cells, and microglia with LPS stimulation [12-14], and MCPIP1 participates in LPS preconditioning/electroacupuncture-pretreatment-induced ischemic brain tolerance [14,15]. The present study examined whether MCPIP1 is involved in minocycline-treatment-induced neuroprotection against cerebral ischemia/reperfusion injury in neuronal cultures and in vivo using MCPIP1-deficient mice.
Animals and minocycline treatment
MCPIP1 knockout mice were established as previously described . Briefly, MCPIP1−/− mice were generated by homologous recombination in embryonic stem cells from C57/BL6 background mice. Exons 3, 4, 5, and most part of 6 of mouse MCPIP1 were replaced with a LacZ-neomycin cassette in embryonic stem cells established from C57/BL6 mice and established MCPIP1−/− mice in pure C57/BL6 background. The absence of MCPIP1 protein in MCPIP−/− mice was confirmed by immunoblotting. In all experiments, 8- to 9-week-old mice were used. All experimental procedures were approved by the Institutional Animal Care and Use Committee of University of Central Florida. We performed all the experiments by using littermate mice. Minocycline treatment was performed following a modification of the method reported by Yrjanheikki and colleagues . Twelve hours before ischemia or 2 h after stroke, mice were injected intraperitoneally with 90 mg/kg of minocycline hydrochloride (Sigma, USA). Thereafter, the animals were injected twice a day, at a dose of 90 mg/kg, after ischemia until sacrificed. Control groups were treated with the same volume of saline starting 12 h before and after stroke.
Mice focal brain ischemia reperfusion model
For focal brain ischemia, mouse transient middle cerebral artery occlusion (MCAO) was produced by filament occlusion of the right MCA as previously described . In brief, mice were anesthetized with isoflurane (induction with 3%; maintenance with 1.2%) in oxygen-enriched air by facemask, and rectal temperature was controlled at 37°C ± 0.5°C throughout the experiment with heating lamps. Unilateral MCAO was performed by inserting a 7-0 nylon monofilament into the internal carotid artery via an external carotid artery stump and then positioning the filament tip for occlusion at a distance of 8 to 9 mm beyond the internal carotid/pterygopalatine artery bifurcation. MCA was occluded for 120 min followed by reperfusion.
Brain infarction measurement
The brains were stained with 2,3,5-triphenyltetrazolium chloride (TTC) ( Sigma, USA ) to determine infarct volume . After 2 h of MCAO and 48 h of reperfusion, mice were anesthetized with 4% isoflurane and brains were removed and sectioned coronally at a thickness of 2 mm and incubated in 2% TTC at 37°C for 20 min. Brain slices were then fixed in 4% paraformaldehyde at 4°C overnight and scanned into a computer and quantified using the Image J software. Infarct volume was expressed as a percentage of the contralateral hemisphere. Eight male mice were used for each group.
Neurological function assessment
The functional outcome of the animals was assessed at 48 h after ischemic/reperfusion. A modified Bederson score  was determined according to the following scoring system: 0, no deficit; 1, forelimb flexion; 2, as for 1, plus decreased resistance to lateral push; 3, unidirectional circling; 4, longitudinal spinning or seizure activity; and 5, no movement. Forty-eight hours after surgery, the foot fault test was performed. Ten male mice were used in each group.
Brain edema measurement
The mice were anesthetized with 4% isoflurane and brains were removed at 48 h after MCAO. The brains were weighed to obtain the wet weight and were then dried at 105°C for 24 h before measuring dry weight. Brain moisture content (%) was calculated as follows: 100 × (wet weight − dry weight)/wet weight. There were ten mice in each group.
Cell culture and transfections
Primary culture of mouse cortical neurons was prepared using 18-day-old (E18) embryos from C57 BL/6 J wild type and MCPIP1−/− mouse by the method reported  with some modifications. Briefly, the mouse brain cortex was dissected and minced and digested in 0.25% trypsin in HEPES-buffered Hank’s balanced salt solution (HBSS) without calcium or magnesium at 37°C for 10 min. The tissue was washed and dissociated mechanically in HBSS buffer by using a Pasteur pipette. The cell suspension was laid on Hanks’ balanced salt solution containing 4% BSA and centrifuged at 1,000 rpm for 5 min. The pellet was resuspended in Neurobasal-A medium with B-27 supplement, 0.25 mmol/L Glutamax-1, 40 U/mL penicillin, 40 μg/mL streptomycin (Neurobasal-A/B-27), and 10% dialyzed horse serum. Cells were plated at in poly-L-lysine-coated 24-well plates at 6 × 105 cells per well. Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2. Half of the medium was replaced with Neurobasal-A/B-27, 10% fetal bovine serum, and 5% horse serum twice a week. For the oxygen glucose deprivation (OGD), we replaced the growth medium with glucose-free culture medium (2 mL per well) and put the plates into an incubator under 95% N2 and 5% CO2 at 37°C for 120 min. Then, cells were returned to the normal feeding medium and incubated under normal conditions at 37°C for our studies. Control cell cultures not deprived of oxygen and glucose were incubated under normal conditions. Minocycline (10 μM) was added to the culture 12 h prior to OGD treatment. Referring to the methods in the report , transfections of neurons at day 5 in vitro (DIV5) with MCPIP1 siRNA (4390771, Life Technologies) and negative control siRNA (4390843, Life Technologies) were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Twenty-four hours later, the cells were treated with or without minocycline (10 μM) for 12 h prior OGD treatment.
MTT and trypan blue exclusion assay to determine cell viability
Primary neuron-glial cells were seeded in 24-well plate. Cells were treated with OGD in the presence or absence of minocycline (10 μM). Twenty-four hours after OGD, examination of cell damage was quantitatively assessed by measuring the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)  and trypan blue inclusion . MTT (Sigma-Aldrich, USA) was added (final concentration, 0.5 mg/mL) to each well. After 3 h of additional incubation, 100 μL of a solution of 10% sodium dodecyl sulfate (SDS) and 0.01 N HCl was added to dissolve the crystals for 16 h. Absorbance values at the test wavelength of 570 nm and the reference wavelength of 630 nm were determined with an automatic microplate reader. Cell survival was quantitated after trypan blue staining by cell counting. Trypan blue (Sigma, USA) (5%) was added to culture wells, and stained (dead) and unstained (live) cells were counted in five high-power (×200) fields per culture. The extent of cell death was expressed as the number of trypan-blue-positive cells as a percent of the total number of cells counted. At least 200 cells were counted per culture.
Quantitative real-time PCR
Quantitative real-time PCR was performed as previously described . Briefly, total RNA was isolated using RNA STAT-60 reagent (Tel-Test, Inc., USA) after removing the genomic DNA using DNase I (Ambion, USA), and 2.0 μg of total RNA from microglia or mouse brain tissue was reverse-transcribed to cDNA using a commercially available kit (Applied Biosystems, USA). Quantitative real-time PCR was performed with iCycler Thermal Cycler (Bio-Rad, USA) using 2X SYBR Green master mixes (Bio-Rad, USA). Forty cycles were conducted as follows: 95°C for 30 s, 60°C for 30 s, proceeded by 10 min at 95°C for polymerase activation. Quantification was performed by the delta cycle time method, with mouse or rat β-actin used for normalization. The mouse specific primers (IDT, USA) are as follows: MCPIP1: F: 5′-CCCCCTGACGACCCTTTAG, R: 5′-GGCAGTGGTTTCTTACGAAGGA; TNFα: F: 5′-CTGAGGTCAATCTGCCCAAGTAC, R: 5′-CTTCACAGAGCAATGACTCCAAAG; IL-1β: F: 5′-GCCCATCCTCTGTGACTCAT, R: 5′-AGGCCACAGGTATTTTGTCG; IL-6: F: 5′-TCGTGGAAATGAGAAAAGAGTTG, R: 5′-AGTGCATCATCGTTGTTCATACA; MCP-1: F: 5′-CCATCTCTGACCTGCTCTTCCT, R: -AGACCCACTCATTTGCAGCAT; β-actin: F: 5′-AAATCGTGCGTGACATCAAAGA, R: 5′-GGCCATCTCCTGCTCGAA. The rat specific primers are as follows: TNFα: F: 5′-TCAGCCGATTTGCCATTTC -3′, R: 5′-AGGGCTCTTGATGGCAGAGA-3′; β-actin: F: 5′-GCCTCACTGTCCACCTTCCA-3′, R: 5′-GGGCCGGACTCATCGTACT-3′. Eight male mice were used in each group.
Immunoblot was performed as previously described . Proteins from mouse brain tissue were extracted and protein concentrations were determined by the Bradford method (Bio-Rad, USA) with bovine serum albumin as the standard. Proteins (50 μg) were separated by SDS-PAGE and transferred onto nitrocellulose membranes in a transfer buffer containing 0.1% SDS. The membranes were treated with 5% nonfat dry milk in 0.05% Tween 20 in Tris-buffered saline (TTBS) for 2 h and incubated with the primary antibodies against MCPIP1 (Santa Cruz, USA), phosphor-p-65 (Cell Signaling, USA), p-65 (Cell Signaling, USA) at a 1:1,000 dilution in the blocking buffer, 4°C, gently shaking, overnight. After being washed with TTBS three times for 10 min each, the membranes were incubated with a 1:2,000 dilution of secondary antibody (Santa Cruz, USA) in TTBS for 1 h. Following three 10-min washes with TTBS, membranes were incubated with SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA) and exposed to x-ray film. The intensity of bands was quantified by AlphaImage 2200 (AlphaInnotech, USA). The ratios between interested protein bands and the loading control (β-actin, total p-65) were calculated, and the data are expressed as the normalized folds with respect to sham. Six male mice were used in each group.
Immunohistochemistry was performed as previously described . At 24 h after minocycline treatment, mice were transcardially perfused under anesthesia with ice-cold phosphate-buffered saline and then with 4% paraformaldehyde. Brains were removed and fixed overnight in 4% paraformaldehyde at 4°C. The brains were sectioned coronally at 30-μm thickness in ice-cold phosphate-buffered saline using a vibrating microtome (Leica Microsystems). The sections were placed in an anti-freeze solution and stored at −20°C for later use. They were washed, the nonspecific binding sites on sections were blocked with 3% bovine serum albumin, and incubated overnight with primary antibody against glial fibrillary acidic protein (GFAP), primary antibody against CD11b (BD Biosciences Pharmingen, San Diego, CA, USA), primary antibody against neuron-specific enolase (NSE; Invitrogen, USA), primary antibody against MCPIP1 (Santa Cruz Biotechnology, Dallas, Texas, USA), AlexaFluor®-488-conjugated secondary antibody (Invitrogen, USA), and AlexaFluor®-594-conjugated secondary antibody (Invitrogen, USA) and scanned under a fluorescence microscope (Leica TCS SP5) at × 400 magnification. Three fields per section were captured and analyzed. Six male mice were used in each group.
The data are presented as mean ± SD. Multiple comparisons were evaluated by one-way ANOVA followed by the Tukey or Dunnett test. Two-group comparisons were analyzed by the two-tailed Student t test. For all analyses, a value of P < 0.05 was considered significant.
MCPIP1 induction in mouse brain by minocycline
Loss of minocycline-treatment-induced tolerance to ischemic stroke by MCPIP1 deficiency
Proinflammatory cytokine expression
Minocycline protection from OGD-induced neuronal damage via induction of MCPIP1 in neurons
Activation of NF-κB-signaling pathway
Many studies have shown that doxycycline and minocycline play anti-inflammatory and neuroprotective effects in ischemic brain injury. This action is completely independent and distinct from their antimicrobial action [3,8,19-22]. It has been well known that ischemic stroke includes secondary inflammation that plays a significant part in the devastating consequences of ischemic insult [23-27]. Although numerous studies have shown that minocycline can provide significant neuroprotection against ischemic brain injury and inhibit inflammatory responses such as microglial activation and proinflammatory cytokine generation [3,27-29], the molecular mechanisms that contribute to the alleviation of brain inflammation after ischemia by minocycline are not well understood. The present study is the first to reveal the role of MCPIP1 in minocycline-treatment-induced cerebral ischemic protection. MCPIP1 was first identified as a protein induced in human peripheral blood monocyte by the chemokine MCP-1 . MCPIP1 has been demonstrated to have the ability to suppress inflammation [10,11,30]. MCPIP1 negatively affects inflammatory gene expression and NF-κB activation in response to LPS [10,11]. In our previous studies, MCPIP1 was also found to be inducibly expressed in macrophages, macroglia, and endothelial cells with LPS stimulation [12-14]. It was also shown that MCPIP1 participates in LPS and electroacupuncture preconditioning-induced ischemic brain tolerance . The recent study  showed that MCPIP1 can be translationally controlled by some other proinflammatory cytokines such as IL-17. All of these investigations indicated that MCPIP1 may act as an inducible endogenous negative feedback regulator of inflammation and could play a highly beneficial role in human inflammation-related diseases including stroke. In the present study, we found that MCPIP1 was significantly induced in mouse brain by minocycline treatment, which suggested that MCPIP1 may be involved in minocycline-induced neuroprotection after ischemic stroke. In addition, we observed that brain infarct volumes, brain edema, and neurological functions after stroke were significantly alleviated by minocycline treatment in wild type mice, whereas in MCPIP1-deficient mice, minocycline treatment failed to improve these outcomes of ischemia, which indicated that MCPIP1 may participate in minocycline-induced neuroprotection in ischemic stroke. Many studies have demonstrated that minocycline is an ideal therapeutic agent for stroke. Our results show that administration of minocycline before or after stroke afforded protection against stroke damage. Of course, the post-treatment paradigm of minocycline indicates more clinical significance in its potential therapeutic application for stroke in the future. The novelty of the present study is that MCPIP1 mediates minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury whether the drug is ministered before or after stroke. In both cases, minocycline induced MCPIP1 in the brain and afforded protection against ischemic brain damage.
It has been well established that proinflammatory gene expression leads to stroke damage [25,32]. During brain ischemia, proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and chemokines such as CINC and MCP-1 are produced by a variety of activated cell types, including endothelial cells, microglia, astrocytes, and neurons . Blocking the production of these proinflammatory cytokines would be an important strategy to protect against ischemia brain injury. In this study, we observed that TNFα, IL-1β, IL-6, and MCP-1 expressions were significantly reduced at 24 h after MCAO by minocycline treatment. In MCPIP1-deficient mice, minocycline treatment failed to suppress the production of such cytokine. Furthermore, we found that expression of MCPIP1 protein was upregulated by minocycline treatment mainly in neurons and microglia, which are the main source of proinflammatory cytokines during ischemia. These results implied that MCPIP1 induction by minocycline may play a beneficial role by inhibiting the generation of proinflammatory cytokines in neurons and microglia during brain ischemia. Activation of NF-κB-signaling pathways leads to inflammatory cytokine production . In our previous study, we found that MCPIP1 can also act as a deubiquitinase to negatively regulate NF-κB signaling by targeting TNF receptor-associated factors (TRAFs) [11,33]. In the present study, we found that phosphorylation of p-65 was significantly reduced at 24 h after MCAO in minocycline-treated wild type mice compared to that of the control. In MCPIP1-deficient mice, there was no significant difference on p-65 phosphorylation level between the minocycline-treated and control group without minocycline treatment. Our study suggested that enhanced activation of NF-κB-signaling pathway in MCPIP1-deficient mice leads to increased proinflammatory cytokine production after brain ischemia with minocycline treatment and that MCPIP1 is involved in minocycline-treatment-induced inhibition of the NF-κB-signaling pathway after ischemic stroke. In the present study, minocycline treatment showed significant neuroprotection in mice subjected to focal brain ischemia by MCAO, which is consistent with other reports. However, we found there was significant loss of minocycline-treatment-induced ischemic brain tolerance in MCPIP1-deficient mice after ischemic stroke, which indicated that MCPIP1 may mediate the beneficial role in minocycline-treatment-induced neuroprotection after focal brain ischemia.
It is possible that the absence of MCPIP1 in the mice creates systemic inflammation that minocycline treatment cannot overcome. However, our in vitro studies in mixed neuron-glia cells and primary cortical neurons indicated that minocycline-pretreatment-induced neuroprotection is, at least partly, via MCPIP1, as absence of MCPIP1 in mixed neuron-glia cells and knockdown of MCPIP1 in primary cortical neurons with OGD treatment resulted in a loss of minocycline-induced protection, which could largely exclude the potential affects of systemic consequence resulting from in vivo studies of general knockout mice. Considering the other experimental results in this study, including that MCPIP1 can be significantly induced by minocycline treatment in the brain, and that MCPIP1 has been identified as an important inducible anti-inflammatory regulator in stroke pathophysiology , it would appear more likely that MCPIP1 actually participates in the minocycline-treatment-induced neuroprotection. Mice with brain-specific MCPIP1 deficiency might provide a suitable model to explore the role of MCPIP1 in ischemic-stroke-induced brain damage without the complication caused by the general knockout of MCPIP1. Based on our in vivo and in vitro studies, we may conclude that MCPIP1 induction is involved in minocycline-induced neuroprotection from ischemic brain injury.
All these findings indicate that the endogenous inducible MCPIP1 protein may serve as an important common shared mediator which performs negative feedback to reduce the inflammatory responses caused by a wide range of hazardous stresses.
This work was supported by James & Ester King Biomedical Research Grant 08KN-03 (to JL), National Institutes of Health grant HL69458 (to PEK) and Zhejiang Provincial Natural Science Foundation of China Grant LY14H270013 (to ZJ).
- Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41:1084–99.View ArticlePubMed CentralPubMedGoogle Scholar
- Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011;14:1363–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci. 1999;96:13496–500.View ArticlePubMed CentralPubMedGoogle Scholar
- Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002;52:54–61.View ArticlePubMedGoogle Scholar
- Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med. 2003;348:1365–75.View ArticlePubMedGoogle Scholar
- Henninger N, Fisher M. Normobaric hyperoxia—a promising approach to expand the time window for acute stroke treatment. Cerebrovasc Dis. 2006;21:134–6.View ArticlePubMedGoogle Scholar
- Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, et al. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke. 2008;39:951–8.View ArticlePubMedGoogle Scholar
- Fagan SC, Cronic LE, Hess DC. Minocycline development for acute ischemic stroke. Transl Stroke Res. 2011;2:202–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res. 2006;98:1177–85.View ArticlePubMed CentralPubMedGoogle Scholar
- Liang J, Wang J, Azfer A, Song W, Tromp G, Kolattukudy PE, et al. A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem. 2008;283:6337–46.View ArticlePubMedGoogle Scholar
- Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling. J Exp Med. 2010;207:2959–73.View ArticlePubMed CentralPubMedGoogle Scholar
- Liang J, Song W, Tromp G, Kolattukudy PE, Fu M. Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation. PLoS One. 2008;3:e2880.View ArticlePubMed CentralPubMedGoogle Scholar
- Qi Y, Liang J, She ZG, Cai Y, Wang J, Lei T, et al. MCP-induced protein 1 suppresses TNFalpha-induced VCAM-1 expression in human endothelial cells. FEBS Lett. 2010;584:3065–72.View ArticlePubMed CentralPubMedGoogle Scholar
- Liang J, Wang J, Saad Y, Warble L, Becerra E, Kolattukudy PE. Participation of MCP-induced protein 1 in lipopolysaccharide preconditioning-induced ischemic stroke tolerance by regulating the expression of proinflammatory cytokines. J Neuroinflammation. 2011;8:182.View ArticlePubMed CentralPubMedGoogle Scholar
- Jin Z, Liang J, Wang J, Kolattukudy PE. Delayed brain ischemia tolerance induced by electroacupuncture pretreatment is mediated via MCP-induced protein 1. J Neuroinflammation. 2013;10:63.View ArticlePubMed CentralPubMedGoogle Scholar
- Araki E, Forster C, Dubinsky JM, Ross ME, Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke. 2001;32(10):2370–5.View ArticlePubMedGoogle Scholar
- Qiao Y, Ouyang YB, Giffard RG. Overexpression of HDJ-2 protects astrocytes from ischemia-like injury and reduces redistribution of ubiquitin staining in vitro. J Cereb Blood Flow Metab. 2003;23(10):1113–6.View ArticlePubMedGoogle Scholar
- Kudo M, Aono M, Lee Y, Massey G, Pearlstein RD, Warner DS. Absence of direct antioxidant effects from volatile anesthetics in primary mixed neuronal-glial cultures. Anesthesiology. 2001;94(2):303–212.View ArticlePubMedGoogle Scholar
- Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998;95(26):15769–74.View ArticlePubMed CentralPubMedGoogle Scholar
- Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic disease. Clin Neuropharmacol. 2004;27(6):293–8.View ArticlePubMedGoogle Scholar
- Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006;7:56.View ArticlePubMed CentralPubMedGoogle Scholar
- Liu Z, Fan Y, Won SJ, Neumann M, Hu D, Zhou L, et al. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke. 2007;38(1):146–52.View ArticlePubMedGoogle Scholar
- Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK. Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor. J Cereb Blood Flow Metab. 2001;21:683–9.View ArticlePubMedGoogle Scholar
- Minami M, Katayama T, Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci. 2006;100:461–70.View ArticlePubMedGoogle Scholar
- Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55(3):310–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192–9.View ArticlePubMedGoogle Scholar
- Haines BA, Mehta SL, Pratt SM, Warden CH, Li PA. Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines. J Cereb Blood Flow Metab. 2010;30:1825–33.View ArticlePubMed CentralPubMedGoogle Scholar
- Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006;37(4):1087–93.View ArticlePubMedGoogle Scholar
- Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184(1–2):53–68.View ArticlePubMed CentralPubMedGoogle Scholar
- Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009;458:1185–90.View ArticlePubMedGoogle Scholar
- Dhamija S, Winzen R, Doerrie A, Behrens G, Kuehne N, Schauerte C, et al. Interleukin-17 (IL-17) and IL-1 activate translation of overlapping sets of mRNAs, including that of the negative regulator of inflammation, MCPIP1. J Biol Chem. 2013;288(26):19250–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Huang J, Upadhyay U, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232–45.View ArticlePubMedGoogle Scholar
- Niu J, Wang K, Graham S, Azfer A, Kolattukudy PE. MCP-1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-кB activation via inhibition of IкB kinase activation. J Mol Cell Cardiol. 2011;51:177–86.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.